The relative contributions of infectious and mitotic spread to HTLV-1 persistence.


Journal

PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922

Informations de publication

Date de publication:
09 2020
Historique:
received: 04 10 2019
accepted: 31 07 2020
revised: 29 09 2020
pubmed: 18 9 2020
medline: 21 10 2020
entrez: 17 9 2020
Statut: epublish

Résumé

Human T-lymphotropic virus type-1 (HTLV-1) persists within hosts via infectious spread (de novo infection) and mitotic spread (infected cell proliferation), creating a population structure of multiple clones (infected cell populations with identical genomic proviral integration sites). The relative contributions of infectious and mitotic spread to HTLV-1 persistence are unknown, and will determine the efficacy of different approaches to treatment. The prevailing view is that infectious spread is negligible in HTLV-1 persistence beyond early infection. However, in light of recent high-throughput data on the abundance of HTLV-1 clones, and recent estimates of HTLV-1 clonal diversity that are substantially higher than previously thought (typically between 104 and 105 HTLV-1+ T cell clones in the body of an asymptomatic carrier or patient with HTLV-1-associated myelopathy/tropical spastic paraparesis), ongoing infectious spread during chronic infection remains possible. We estimate the ratio of infectious to mitotic spread using a hybrid model of deterministic and stochastic processes, fitted to previously published HTLV-1 clonal diversity estimates. We investigate the robustness of our estimates using three alternative estimators. We find that, contrary to previous belief, infectious spread persists during chronic infection, even after HTLV-1 proviral load has reached its set point, and we estimate that between 100 and 200 new HTLV-1 clones are created and killed every day. We find broad agreement between all estimators. The risk of HTLV-1-associated malignancy and inflammatory disease is strongly correlated with proviral load, which in turn is correlated with the number of HTLV-1-infected clones, which are created by de novo infection. Our results therefore imply that suppression of de novo infection may reduce the risk of malignant transformation.

Identifiants

pubmed: 32941445
doi: 10.1371/journal.pcbi.1007470
pii: PCOMPBIOL-D-19-01729
pmc: PMC7524007
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1007470

Subventions

Organisme : Wellcome Trust
ID : 103865
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J007439/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 207477/Z/17/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 100291
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1001052
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 091845
Pays : United Kingdom
Organisme : Medical Research Council
ID : J007439
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Lancet Oncol. 2014 Oct;15(11):e517-26
pubmed: 25281470
Blood. 2014 Jun 19;123(25):3925-31
pubmed: 24735963
Blood. 1996 Dec 15;88(12):4646-50
pubmed: 8977257
Front Microbiol. 2012 Nov 15;3:388
pubmed: 23162541
J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S92-9
pubmed: 8797710
J Virol. 1995 May;69(5):2863-8
pubmed: 7707509
Int J Cancer. 2004 Jul 1;110(4):621-5
pubmed: 15122598
Oncogene. 2000 Oct 12;19(43):4954-60
pubmed: 11042682
Blood. 2011 Mar 17;117(11):3113-22
pubmed: 21228324
AIDS Res Hum Retroviruses. 2013 Feb;29(2):359-64
pubmed: 22894552
Science. 2001 May 11;292(5519):1106-9
pubmed: 11352065
Elife. 2020 Mar 18;9:
pubmed: 32187010
Curr Opin Neurobiol. 1993 Oct;3(5):773-8
pubmed: 8260828
Bull Math Biol. 2008 Nov;70(8):2283-302
pubmed: 18716844
J Infect Dis. 2005 Apr 1;191(7):1140-7
pubmed: 15747250
Sci Rep. 2017 Dec 1;7(1):16788
pubmed: 29196717
PLoS Pathog. 2013;9(4):e1003263
pubmed: 23592987
Bioinformatics. 2012 Mar 15;28(6):755-62
pubmed: 22238265
Philos Trans R Soc Lond B Biol Sci. 2015 Aug 19;370(1675):
pubmed: 26150657
PLoS Pathog. 2008 Mar 21;4(3):e1000027
pubmed: 18369476
Blood. 1992 Aug 15;80(4):1012-6
pubmed: 1498321
PLoS Comput Biol. 2014 Jun 19;10(6):e1003646
pubmed: 24945836
J Virol. 1999 Dec;73(12):10289-95
pubmed: 10559346
Virol J. 2014 Sep 30;11:172
pubmed: 25270762
J Neurovirol. 2001 Jun;7(3):228-34
pubmed: 11517397
Immunol Today. 1999 May;20(5):220-7
pubmed: 10322301
J Neurovirol. 1998 Dec;4(6):586-93
pubmed: 10065900
Nat Rev Dis Primers. 2015 Jun 18;1:15012
pubmed: 27188208
Proc Natl Acad Sci U S A. 2007 May 8;104(19):8035-40
pubmed: 17483473
J Clin Invest. 2010 Jun;120(6):1885-94
pubmed: 20440073

Auteurs

Daniel J Laydon (DJ)

MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, United Kingdom.
Section of Immunology, Wright-Fleming Institute, Imperial College School of Medicine, London, United Kingdom.

Vikram Sunkara (V)

Department of Mathematics and Computer Science, Freie Universität, Arnimallee, Berlin, Germany.

Lies Boelen (L)

Section of Immunology, Wright-Fleming Institute, Imperial College School of Medicine, London, United Kingdom.

Charles R M Bangham (CRM)

Section of Immunology, Wright-Fleming Institute, Imperial College School of Medicine, London, United Kingdom.

Becca Asquith (B)

Section of Immunology, Wright-Fleming Institute, Imperial College School of Medicine, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH